Literature DB >> 28372839

Orthogonal liquid chromatography-mass spectrometry methods for the comprehensive characterization of therapeutic glycoproteins, from released glycans to intact protein level.

Eric Largy1, Fabrice Cantais1, Géry Van Vyncht1, Alain Beck2, Arnaud Delobel3.   

Abstract

Proteins are increasingly used as therapeutics. Their characterization is challenging due to their size and inherent heterogeneity notably caused by post-translational modifications, among which glycosylation is probably the most prominent. The glycosylation profile of therapeutic proteins must therefore be thoroughly analyzed. Here, we illustrate how the use of a combination of various cutting-edge LC or LC/MS(/MS) methods, and operating at different levels of analysis allows the comprehensive characterization of both the N- and O-glycosylations of therapeutic proteins without the need for other approaches (capillary electrophoresis, MALDI-TOF). This workflow does not call for the use of highly specialized/custom hardware and software nor an extensive knowledge of glycan analysis. Most notably, we present the point of view of a contract research organization, with the constraints associated to the work in a regulated environment (GxP). Two salient points of this work are i) the use of mixed-mode chromatography as a fast and straightforward mean of profiling N-glycans sialylation as well as an orthogonal method to separate N-glycans co-eluting in the HILIC mode; and ii) the use of widepore HILIC/MS to analyze challenging N/O-glycosylation profiles at both the peptide and subunit levels. A particular attention was given to the sample preparations in terms of duration, specificity, versatility, and robustness, as well as the ease of data processing.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  High-resolution mass spectrometry; Hydrophilic interaction chromatography; Mixed-mode chromatography; Porous graphitic carbon chromatography; Protein glycosylation; Therapeutic proteins

Mesh:

Substances:

Year:  2017        PMID: 28372839     DOI: 10.1016/j.chroma.2017.02.072

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  8 in total

1.  Characterization of Glycosylated Proteins at Subunit Level by HILIC/MS.

Authors:  Valentina D'Atri; Davy Guillarme
Journal:  Methods Mol Biol       Date:  2021

2.  Glycosylation of Therapeutic Proteins: A Critical Quality Attribute.

Authors:  Arnaud Delobel
Journal:  Methods Mol Biol       Date:  2021

3.  Fast Afucosylation Profiling of Glycoengineered Antibody Subunits by Middle-Up Mass Spectrometry.

Authors:  Elsa Wagner-Rousset; Olivier Colas; Stéphane Chenu; Yannis-Nicolas François; Davy Guillarme; Sarah Cianferani; Yury O Tsybin; Jonathan Sjögren; Arnaud Delobel; Alain Beck
Journal:  Methods Mol Biol       Date:  2021

4.  Lectin and Liquid Chromatography-Based Methods for Immunoglobulin (G) Glycosylation Analysis.

Authors:  Tea Petrović; Irena Trbojević-Akmačić
Journal:  Exp Suppl       Date:  2021

5.  Enhanced protocol for quantitative N-linked glycomics analysis using Individuality Normalization when Labeling with Isotopic Glycan Hydrazide Tags (INLIGHT)™.

Authors:  Jaclyn Gowen Kalmar; Karen E Butler; Erin S Baker; David C Muddiman
Journal:  Anal Bioanal Chem       Date:  2020-08-26       Impact factor: 4.142

Review 6.  Monitoring of immunoglobulin N- and O-glycosylation in health and disease.

Authors:  Noortje de Haan; David Falck; Manfred Wuhrer
Journal:  Glycobiology       Date:  2020-03-20       Impact factor: 4.313

7.  Synthesis of new asparagine-based glycopeptides for future scanning tunneling microscopy investigations.

Authors:  Laura Sršan; Thomas Ziegler
Journal:  Beilstein J Org Chem       Date:  2020-04-30       Impact factor: 2.883

8.  A new approach for identifying positional isomers of glycans cleaved from monoclonal antibodies.

Authors:  Irina Dyukova; Ahmed Ben Faleh; Stephan Warnke; Natalia Yalovenko; Vasyl Yatsyna; Priyanka Bansal; Thomas R Rizzo
Journal:  Analyst       Date:  2021-07-26       Impact factor: 4.616

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.